# Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure

> **NCT01318525** · PHASE2 · UNKNOWN · sponsor: **Alfact Innovation** · enrollment: 60 (estimated)

## Conditions studied

- Liver Failure, Acute

## Interventions

- **DRUG:** ALF-5755
- **DRUG:** Saline solution (0.9% NaCl)

## Key facts

- **NCT ID:** NCT01318525
- **Lead sponsor:** Alfact Innovation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2010-10
- **Primary completion:** 2012-05
- **Final completion:** 2012-09
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2011-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01318525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01318525, "Efficacy & Safety of ALF-5755 in Patients With Nonacetaminophen Severe Acute Hepatitis & Early Stage Acute Liver Failure". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01318525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*